Coming Soon

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This study is being done to determine whether older adult patients diagnosed with mantle cell lymphoma require continuous treatment with the study drug zanubrutinib once remission has been retained.

Age & Gender

60 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Anne Beaven
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lymphoma)

IRB Number

23-2508

ClinicalTrials.gov

NCT05976763

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.